{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:54:45Z","timestamp":1793361285426,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000341","name":"Arthritis Research UK","doi-asserted-by":"publisher","award":["20621"],"award-info":[{"award-number":["20621"]}],"id":[{"id":"10.13039\/501100000341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000836","name":"University of Liverpool","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003390","name":"Fritz Thyssen Stiftung","doi-asserted-by":"publisher","award":["10.15.1.019MN"],"award-info":[{"award-number":["10.15.1.019MN"]}],"id":[{"id":"10.13039\/501100003390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003390","name":"Fritz Thyssen Stiftung","doi-asserted-by":"publisher","award":["60.364"],"award-info":[{"award-number":["60.364"]}],"id":[{"id":"10.13039\/501100003390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["MAIN457_FUKH001"],"award-info":[{"award-number":["MAIN457_FUKH001"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013524","name":"Cystinosis Research Network","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013524","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.berh.2018.02.001","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T10:18:19Z","timestamp":1519899499000},"page":"488-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Juvenile-onset systemic lupus erythematosus (jSLE) \u2013 Pathophysiological concepts and treatment options"],"prefix":"10.1016","volume":"31","author":[{"given":"Christian M.","family":"Hedrich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve M.D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Beresford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"22","key":"10.1016\/j.berh.2018.02.001_bib2","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus","volume":"365","author":"Tsokos","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/nrrheum.2013.78","article-title":"Gene-function studies in systemic lupus erythematosus","volume":"9","author":"Crispin","year":"2013","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11926-017-0685-1","article-title":"Epigenetics in SLE","volume":"19","author":"Hedrich","year":"2017","journal-title":"Curr Rheumatol Rep"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3109\/08916934.2013.801462","article-title":"Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells","volume":"47","author":"Hedrich","year":"2014","journal-title":"Autoimmunity"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/epi-2016-0096","article-title":"DNA methylation in systemic lupus erythematosus","volume":"9","author":"Hedrich","year":"2017","journal-title":"Epigenomics"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/nrrheum.2011.15","article-title":"Pediatric SLE\u2013towards a comprehensive management plan","volume":"7","author":"Brunner","year":"2011","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nrrheum.2012.109","article-title":"Paediatric rheumatic disease: lessons from SLE: children are not little adults","volume":"8","author":"Ardoin","year":"2012","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s10067-010-1576-2","article-title":"Early onset systemic lupus erythematosus: differential diagnoses, clinical presentation, and treatment options","volume":"30","author":"Hedrich","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib10","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/0961203308090992","article-title":"Severe clinical course of systemic lupus erythematosus in the first year of life","volume":"17","author":"Zulian","year":"2008","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib11","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/acr.20179","article-title":"Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus","volume":"62","author":"Hersh","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"13","key":"10.1016\/j.berh.2018.02.001_bib12","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1177\/0961203311416694","article-title":"Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis","volume":"20","author":"Livingston","year":"2011","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib13","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.semarthrit.2012.05.001","article-title":"Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis","volume":"42","author":"Livingston","year":"2012","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-016-0621-9","article-title":"Monogenic lupus","volume":"18","author":"Lo","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib15","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nrrheum.2016.186","article-title":"New insights into the immunopathogenesis of systemic lupus erythematosus","volume":"12","author":"Tsokos","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.berh.2018.02.001_bib16","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.clim.2016.03.002","article-title":"Shaping the spectrum - from autoinflammation to autoimmunity","volume":"165","author":"Hedrich","year":"2016","journal-title":"Clin Immunol"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib17","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0030297","article-title":"A\u00a0proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib18","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s11882-014-0448-2","article-title":"Complement deficiencies in systemic lupus erythematosus","volume":"14","author":"Bryan","year":"2014","journal-title":"Curr Allergy Asthma Rep"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib19","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2006-04-015776","article-title":"A\u00a0homozygous fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome","volume":"108","author":"Del-Rey","year":"2006","journal-title":"Blood"},{"issue":"5215","key":"10.1016\/j.berh.2018.02.001_bib20","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1126\/science.7539157","article-title":"Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity","volume":"268","author":"Rieux-Laucat","year":"1995","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib21","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1172\/JCI118892","article-title":"Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease","volume":"98","author":"Wu","year":"1996","journal-title":"J\u00a0Clin Invest"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib22","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11033-012-2075-0","article-title":"Association of Fas gene polymorphisms with systemic lupus erythematosus: a meta-analysis","volume":"40","author":"Xiang","year":"2013","journal-title":"Mol Biol Rep"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/ng.975","article-title":"Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus erythematosus","volume":"43","author":"Al-Mayouf","year":"2011","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF00541153","article-title":"Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus","volume":"1","author":"Chitrabamrung","year":"1981","journal-title":"Rheumatol Int"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib25","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/76032","article-title":"Features of systemic lupus erythematosus in Dnase1-deficient mice","volume":"25","author":"Napirei","year":"2000","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/91070","article-title":"Mutation of DNASE1 in people with systemic lupus erythematosus","volume":"28","author":"Yasutomo","year":"2001","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.cell.2016.05.034","article-title":"Digestion of chromatin in apoptotic cell microparticles prevents autoimmunity","volume":"166","author":"Sisirak","year":"2016","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10067-008-0942-9","article-title":"Chilblain lupus erythematosus\u2013a review of literature","volume":"27","author":"Hedrich","year":"2008","journal-title":"Clin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib29","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00109-007-0199-9","article-title":"A\u00a0mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus","volume":"85","author":"Lee-Kirsch","year":"2007","journal-title":"J\u00a0Mol Med (Berl)"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib30","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1086\/507848","article-title":"Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p","volume":"79","author":"Lee-Kirsch","year":"2006","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.clim.2013.01.003","article-title":"Nucleic acid driven sterile inflammation","volume":"147","author":"Ablasser","year":"2013","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib32","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.cell.2008.06.032","article-title":"Trex1 prevents cell-intrinsic initiation of autoimmunity","volume":"134","author":"Stetson","year":"2008","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib33","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2007.10.017","article-title":"Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease","volume":"131","author":"Yang","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.berh.2018.02.001_bib34","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1749-6632.2011.06220.x","article-title":"Type I interferonopathies: a novel set of inborn errors of immunity","volume":"1238","author":"Crow","year":"2011","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib35","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/art.38008","article-title":"Protein kinase cdelta deficiency causes mendelian systemic lupus erythematosus with B cell-defective apoptosis and hyperproliferation","volume":"65","author":"Belot","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"6883","key":"10.1016\/j.berh.2018.02.001_bib36","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/416860a","article-title":"Protein kinase Cdelta controls self-antigen-induced B-cell tolerance","volume":"416","author":"Mecklenbrauker","year":"2002","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib37","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1084\/jem.20020408","article-title":"Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha","volume":"195","author":"Saijo","year":"2002","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.berh.2018.02.001_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0065-2776(01)76021-X","article-title":"Systemic lupus erythematosus, complement deficiency, and apoptosis","volume":"76","author":"Pickering","year":"2000","journal-title":"Adv Immunol"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib39","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1177\/0961203311404914","article-title":"Clinical presentations and molecular basis of complement C1r deficiency in a male African-American patient with systemic lupus erythematosus","volume":"20","author":"Wu","year":"2011","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib40","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/j.molimm.2007.09.034","article-title":"Genetic analysis of complement C1s deficiency associated with systemic lupus erythematosus highlights alternative splicing of normal C1s gene","volume":"45","author":"Amano","year":"2008","journal-title":"Mol Immunol"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/acr.20361","article-title":"Complement C2 deficiency disarranging innate and adaptive humoral immune responses in a pediatric patient: treatment with rituximab","volume":"63","author":"Hauck","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib42","doi-asserted-by":"crossref","first-page":"717","DOI":"10.7326\/0003-4819-90-4-717_3","article-title":"C2 deficiency and a lupus erythematosus-like illness: family re-evaluation","volume":"90","author":"Wahl","year":"1979","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib43","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.1780300908","article-title":"Deletion of C4A genes in patients with systemic lupus erythematosus","volume":"30","author":"Kemp","year":"1987","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.tim.2015.08.002","article-title":"SAMHD1: at the crossroads of cell proliferation, immune responses, and virus restriction","volume":"23","author":"Ballana","year":"2015","journal-title":"Trends Microbiol"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ajmg.a.36887","article-title":"Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1","volume":"167A","author":"Crow","year":"2015","journal-title":"Am J Med Genet"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib46","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1002\/art.38824","article-title":"Identification of a pathogenic variant in TREX1 in early-onset cerebral systemic lupus erythematosus by Whole-exome sequencing","volume":"66","author":"Ellyard","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrg2571","article-title":"Genetic susceptibility to SLE: new insights from fine mapping and genome-wide association studies","volume":"10","author":"Harley","year":"2009","journal-title":"Nat Rev Genet"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/ng0598-56","article-title":"Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies","volume":"19","author":"Botto","year":"1998","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.autrev.2008.11.004","article-title":"Autoimmune manifestations in primary immune deficiencies","volume":"8","author":"Bussone","year":"2009","journal-title":"Autoimmun Rev"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib50","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1172\/JCI116090","article-title":"Immune complex processing in patients with systemic lupus erythematosus. In\u00a0vivo imaging and clearance studies","volume":"90","author":"Davies","year":"1992","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib51","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.4049\/jimmunol.158.10.4525","article-title":"C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited","volume":"158","author":"Korb","year":"1997","journal-title":"J\u00a0Immunol"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib52","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nri1456","article-title":"A\u00a0protective role for innate immunity in systemic lupus erythematosus","volume":"4","author":"Carroll","year":"2004","journal-title":"Nat Rev Immunol"},{"issue":"22","key":"10.1016\/j.berh.2018.02.001_bib53","doi-asserted-by":"crossref","first-page":"4421","DOI":"10.1182\/blood-2011-12-401133","article-title":"Endocytosis of soluble immune complexes leads to their clearance by FcgammaRIIIB but induces neutrophil extracellular traps via FcgammaRIIA in\u00a0vivo","volume":"120","author":"Chen","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/ng.81","article-title":"Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci","volume":"40","author":"International Consortium for Systemic Lupus Erythematosus G","year":"2008","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib55","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s002510050426","article-title":"IgG receptor polymorphisms: risk factors for disease","volume":"48","author":"van der Pol","year":"1998","journal-title":"Immunogenetics"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib56","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/ng2091","article-title":"Mutations in the gene encoding the 3'-5' DNA exonuclease TREX1 are associated with systemic lupus erythematosus","volume":"39","author":"Lee-Kirsch","year":"2007","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib57","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/gene.2010.73","article-title":"Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort","volume":"12","author":"Namjou","year":"2011","journal-title":"Gene Immun"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib58","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.molcel.2006.06.005","article-title":"The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme a-mediated cell death","volume":"23","author":"Chowdhury","year":"2006","journal-title":"Mol Cell"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib59","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/ard.2010.141697","article-title":"Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients","volume":"70","author":"Webb","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib60","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1172\/JCI24895","article-title":"Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus","volume":"115","author":"Katsiari","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib61","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJMoa0707865","article-title":"Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX","volume":"358","author":"Hom","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib62","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ng.71","article-title":"A\u00a0nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus","volume":"40","author":"Nath","year":"2008","journal-title":"Nat Genet"},{"issue":"7303","key":"10.1016\/j.berh.2018.02.001_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature09115","article-title":"Functionally defective germline variants of sialic acid acetylesterase in autoimmunity","volume":"466","author":"Surolia","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.berh.2018.02.001_bib64","first-page":"906086","article-title":"Cyclic AMP-Responsive element modulator alpha polymorphisms are potential genetic risks for systemic lupus erythematosus","volume":"2015","author":"Guo","year":"2015","journal-title":"J\u00a0Immunol Res."},{"issue":"1\u20134","key":"10.1016\/j.berh.2018.02.001_bib65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1159\/000184701","article-title":"Copy number variants in genetic susceptibility and severity of systemic lupus erythematosus","volume":"123","author":"Ptacek","year":"2008","journal-title":"Cytogenet Genome Res"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib66","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1086\/518257","volume":"80","author":"Yang","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib67","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/art.38337","article-title":"Fcgamma receptor IIIa single-nucleotide polymorphisms and haplotypes affect human IgG binding and are associated with lupus nephritis in African Americans","volume":"66","author":"Dong","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib68","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0961203312474704","article-title":"Impaired phagocytosis and susceptibility to infection in pediatric-onset systemic lupus erythematosus","volume":"22","author":"Wu","year":"2013","journal-title":"Lupus"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib69","doi-asserted-by":"crossref","first-page":"R120","DOI":"10.1186\/ar4575","article-title":"Low production of reactive oxygen species in granulocytes is associated with organ damage in systemic lupus erythematosus","volume":"16","author":"Bengtsson","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib70","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/nm.4027","article-title":"Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease","volume":"22","author":"Lood","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib71","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0961203310392421","article-title":"Cellular localization of nuclear antigen during neutrophil apoptosis: mechanism for autoantigen exposure?","volume":"20","author":"Midgley","year":"2011","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib72","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1002\/art.24634","article-title":"The role of neutrophil apoptosis in juvenile-onset systemic lupus erythematosus","volume":"60","author":"Midgley","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib73","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/BOR.0000000000000197","article-title":"The role of neutrophils in the pathogenesis of systemic lupus erythematosus","volume":"27","author":"Smith","year":"2015","journal-title":"Curr Opin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib74","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4049\/jimmunol.1100450","article-title":"Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus","volume":"187","author":"Villanueva","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"73","key":"10.1016\/j.berh.2018.02.001_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001201","article-title":"Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus","volume":"3","author":"Garcia-Romo","year":"2011","journal-title":"Sci Transl Med"},{"issue":"73","key":"10.1016\/j.berh.2018.02.001_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001180","article-title":"Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus","volume":"3","author":"Lande","year":"2011","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib77","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.jaci.2015.04.008","article-title":"Single-cell systems-level analysis of human Toll-like receptor activation defines a chemokine signature in patients with systemic lupus erythematosus","volume":"136","author":"O'Gorman","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib78","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.clim.2006.12.008","article-title":"The TNFalpha locus is altered in monocytes from patients with systemic lupus erythematosus","volume":"123","author":"Sullivan","year":"2007","journal-title":"Clin Immunol"},{"issue":"25","key":"10.1016\/j.berh.2018.02.001_bib79","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa035611","article-title":"Premature coronary-artery atherosclerosis in systemic lupus erythematosus","volume":"349","author":"Asanuma","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib80","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1046\/j.1523-1755.2001.00492.x","article-title":"Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages","volume":"59","author":"Hill","year":"2001","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib81","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1177\/0961203308089410","article-title":"Systemic lupus erythematosus patients have increased number of circulating plasmacytoid dendritic cells, but decreased myeloid dendritic cells with deficient CD83 expression","volume":"17","author":"Jin","year":"2008","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib82","first-page":"509","article-title":"FCgammaRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus","volume":"10","author":"Batteux","year":"1999","journal-title":"Eur Cytokine Netw"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib83","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1136\/annrheumdis-2015-208055","article-title":"Activated T cells enhance interferon-alpha production by plasmacytoid dendritic cells stimulated with RNA-containing immune complexes","volume":"75","author":"Leonard","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib84","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1093\/rheumatology\/ken256","article-title":"Active systemic lupus erythematosus is associated with failure of antigen-presenting cells to express programmed death ligand-1","volume":"47","author":"Mozaffarian","year":"2008","journal-title":"Rheumatology"},{"issue":"23","key":"10.1016\/j.berh.2018.02.001_bib85","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1016\/j.febslet.2011.07.043","article-title":"Regulatory T-cells in systemic lupus erythematosus and rheumatoid arthritis","volume":"585","author":"Chavele","year":"2011","journal-title":"FEBS Lett"},{"issue":"41","key":"10.1016\/j.berh.2018.02.001_bib86","doi-asserted-by":"crossref","first-page":"16606","DOI":"10.1073\/pnas.1210129109","article-title":"cAMP response element modulator alpha controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus","volume":"109","author":"Hedrich","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"10.1016\/j.berh.2018.02.001_bib87","doi-asserted-by":"crossref","first-page":"43429","DOI":"10.1074\/jbc.M111.299339","article-title":"cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus","volume":"286","author":"Hedrich","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"50","key":"10.1016\/j.berh.2018.02.001_bib88","doi-asserted-by":"crossref","first-page":"43437","DOI":"10.1074\/jbc.M111.299313","article-title":"cAMP-responsive element modulator (CREM)alpha protein induces interleukin 17A expression and mediates epigenetic alterations at the interleukin-17A gene locus in patients with systemic lupus erythematosus","volume":"286","author":"Rauen","year":"2011","journal-title":"J\u00a0Biol Chem"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib89","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/1529-0131(200105)44:5<1114::AID-ANR192>3.0.CO;2-B","article-title":"Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus","volume":"44","author":"Enyedy","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib90","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1172\/JCI1457","article-title":"Altered pattern of TCR\/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain","volume":"101","author":"Liossis","year":"1998","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib91","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1172\/JCI22854","article-title":"Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV","volume":"115","author":"Juang","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib92","doi-asserted-by":"crossref","first-page":"8761","DOI":"10.4049\/jimmunol.181.12.8761","article-title":"Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys","volume":"181","author":"Crispin","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib93","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1074\/jbc.M113.523605","article-title":"cAMP responsive element modulator (CREM) alpha mediates chromatin remodeling of CD8 during the generation of CD3+ CD4- CD8- T cells","volume":"289","author":"Hedrich","year":"2014","journal-title":"J\u00a0Biol Chem"},{"issue":"44","key":"10.1016\/j.berh.2018.02.001_bib94","doi-asserted-by":"crossref","first-page":"31880","DOI":"10.1074\/jbc.M113.508655","article-title":"cAMP-responsive element modulator alpha (CREMalpha) trans-represses the transmembrane glycoprotein CD8 and contributes to the generation of CD3+CD4-CD8- T cells in health and disease","volume":"288","author":"Hedrich","year":"2013","journal-title":"J\u00a0Biol Chem"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib95","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.4049\/jimmunol.1402775","article-title":"Programmed cell death 1 and Helios distinguish TCR-alphabeta+ double-negative (CD4-CD8-) T cells that derive from self-reactive CD8 T cells","volume":"194","author":"Rodriguez-Rodriguez","year":"2015","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.berh.2018.02.001_bib96","first-page":"1","article-title":"Alpha beta double negative T cells in children with systemic lupus erythematosus: the relation to disease activity and characteristics","author":"El-Sayed","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib97","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.4049\/jimmunol.1400977","article-title":"IL-2 protects lupus-prone mice from multiple end-organ damage by limiting CD4-CD8- IL-17-producing T cells","volume":"193","author":"Mizui","year":"2014","journal-title":"J\u00a0Immunol"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib98","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11926-016-0617-5","article-title":"Low-Dose IL-2 in the treatment of lupus","volume":"18","author":"Mizui","year":"2016","journal-title":"Curr Rheumatol Rep"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib99","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/annrheumdis-2015-207776","article-title":"Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus","volume":"75","author":"von Spee-Mayer","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jim.2010.06.009","article-title":"Abnormalities of B cell subsets in patients with systemic lupus erythematosus","volume":"363","author":"Dorner","year":"2011","journal-title":"J\u00a0Immunol Methods"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib101","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4049\/jimmunol.172.2.812","article-title":"TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma","volume":"172","author":"Batten","year":"2004","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib102","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.coph.2004.02.009","article-title":"The role of the BAFF\/APRIL system in B cell homeostasis and lymphoid cancers","volume":"4","author":"Mackay","year":"2004","journal-title":"Curr Opin Pharmacol"},{"issue":"16","key":"10.1016\/j.berh.2018.02.001_bib103","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib104","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1002\/art.38742","article-title":"Impaired suppressive capacity of activation-induced regulatory B cells in systemic lupus erythematosus","volume":"66","author":"Gao","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib105","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.4049\/jimmunol.165.10.5970","article-title":"Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus","volume":"165","author":"Odendahl","year":"2000","journal-title":"J\u00a0Immunol"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib106","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.coi.2011.10.007","article-title":"B\u00a0cells and autoimmunity","volume":"23","author":"Pillai","year":"2011","journal-title":"Curr Opin Immunol"},{"issue":"5638","key":"10.1016\/j.berh.2018.02.001_bib107","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant autoantibody production by early human B cell precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib108","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","article-title":"European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib109","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1136\/annrheumdis-2016-211001","article-title":"European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib110","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1136\/annrheumdis-2017-211898","article-title":"European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative","volume":"76","author":"Groot","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib111","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/art.1780220901","article-title":"Does corticosteroid therapy affect the survival of patients with systemic lupus erythematosus?","volume":"22","author":"Albert","year":"1979","journal-title":"Arthritis Rheum"},{"issue":"15","key":"10.1016\/j.berh.2018.02.001_bib112","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1056\/NEJM199704103361506","article-title":"Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases","volume":"336","author":"Barnes","year":"1997","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib113","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1172\/JCI112427","article-title":"Mechanism of action of glucocorticosteroids. Inhibition of T cell proliferation and interleukin 2 production by hydrocortisone is reversed by leukotriene B4","volume":"77","author":"Goodwin","year":"1986","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib114","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1136\/ard.2008.092163","article-title":"Dose-related patterns of glucocorticoid-induced side effects","volume":"68","author":"Huscher","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib115","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/thorax.55.7.603","article-title":"Molecular mechanisms of glucocorticoid action: what is important?","volume":"55","author":"Newton","year":"2000","journal-title":"Thorax"},{"key":"10.1016\/j.berh.2018.02.001_bib116","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1749-6632.2011.06263.x","article-title":"Treatment of systemic lupus erythematosus: new advances in targeted therapy","volume":"1247","author":"Lo","year":"2012","journal-title":"Ann N Y Acad Sci"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib117","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib118","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1073\/pnas.79.1.175","article-title":"Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells","volume":"79","author":"Ziegler","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.berh.2018.02.001_bib119","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1056\/NEJM199101173240303","article-title":"A\u00a0randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus","volume":"324","author":"Canadian Hydroxychloroquine Study G","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0961203307078579","article-title":"Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus","volume":"16","author":"James","year":"2007","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib121","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1136\/ard.2009.119263","article-title":"Evaluation of the risk of anti-SSA\/Ro-SSB\/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine","volume":"69","author":"Izmirly","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib122","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.2008.101766","article-title":"Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review","volume":"69","author":"Ruiz-Irastorza","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib123","doi-asserted-by":"crossref","first-page":"549","DOI":"10.7326\/0003-4819-125-7-199610010-00003","article-title":"Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial","volume":"125","author":"Gourley","year":"1996","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib124","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/0003-4819-135-4-200108210-00009","article-title":"Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis","volume":"135","author":"Illei","year":"2001","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib125","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.55.4.224","article-title":"Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide","volume":"55","author":"McDermott","year":"1996","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib126","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/1529-0131(199805)41:5<831::AID-ART9>3.0.CO;2-1","article-title":"Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy","volume":"41","author":"Mok","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib127","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1002\/art.1780380815","article-title":"Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year followup study","volume":"38","author":"Radis","year":"1995","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib128","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1681\/ASN.2008101028","article-title":"Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis","volume":"20","author":"Appel","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib129","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa031855","article-title":"Sequential therapies for proliferative lupus nephritis","volume":"350","author":"Contreras","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1191\/0961203305lu2061oa","article-title":"Mycophenolate mofetil in lupus nephritis","volume":"14","author":"Ginzler","year":"2005","journal-title":"Lupus"},{"issue":"21","key":"10.1016\/j.berh.2018.02.001_bib131","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa043731","article-title":"Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis","volume":"353","author":"Ginzler","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib132","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1177\/0961203307084712","article-title":"Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS)","volume":"16","author":"Sinclair","year":"2007","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib133","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/rheumatology\/kep346","article-title":"Influence of race\/ethnicity on response to lupus nephritis treatment: the ALMS study","volume":"49","author":"Isenberg","year":"2010","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib134","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1007\/s00228-008-0478-6","article-title":"Clinical pharmacology and pharmacogenetics of thiopurines","volume":"64","author":"Sahasranaman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib135","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.ki.5001630","article-title":"Azathioprine\/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial","volume":"70","author":"Grootscholten","year":"2006","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib136","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0961203309106602","article-title":"Very long-term outcome of pure lupus membranous nephropathy treated with glucocorticoid and azathioprine","volume":"18","author":"Mok","year":"2009","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib137","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1002\/art.24068","article-title":"Steroid-sparing effects of methotrexate in systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial","volume":"59","author":"Fortin","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib138","first-page":"496","article-title":"[Methotrexate in the therapy of juvenile idiopathic arthritis]","volume":"69","author":"Holzinger","year":"2010","journal-title":"Z\u00a0Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib139","first-page":"354","article-title":"Methotrexate induced false photosensitivity reaction","volume":"12","author":"Neiman","year":"1985","journal-title":"J\u00a0Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib140","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/S1470-2045(10)70210-2","article-title":"New drugs for aggressive B-cell and T-cell lymphomas","volume":"11","author":"Murawski","year":"2010","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib141","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncprheum0424","article-title":"Drug insight: the mechanism of action of rituximab in autoimmune disease\u2013the immune complex decoy hypothesis","volume":"3","author":"Taylor","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib142","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib143","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1177\/0961203310395802","article-title":"Assessment of flares in lupus patients enrolled in a phase II\/III study of rituximab (EXPLORER)","volume":"20","author":"Merrill","year":"2011","journal-title":"Lupus"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib144","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2018.02.001_bib145","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A\u00a0retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib146","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/art.24726","article-title":"Rituximab and lupus: good in real life, bad in controlled trials. Comment on the article by Lu et\u00a0al","volume":"61","author":"Ramos-Casals","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib147","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib148","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib149","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1089\/152581603321210082","article-title":"Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy","volume":"12","author":"Castagnola","year":"2003","journal-title":"J\u00a0Hematother Stem Cell Res"},{"issue":"9","key":"10.1016\/j.berh.2018.02.001_bib150","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/TP.0b013e318188ac0c","article-title":"Prolonged agammaglobulinemia despite unaltered B-cell lymphopoiesis after peritransplant-rituximab administration in a child","volume":"86","author":"Guerin","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib151","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib152","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nri2572","article-title":"Cracking the BAFF code","volume":"9","author":"Mackay","year":"2009","journal-title":"Nat Rev Immunol"},{"issue":"9767","key":"10.1016\/j.berh.2018.02.001_bib153","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.berh.2018.02.001_bib154","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1345\/aph.1P360","article-title":"Belimumab: a BLyS-specific inhibitor for systemic lupus erythematosus","volume":"44","author":"Wiglesworth","year":"2010","journal-title":"Ann Pharmacother"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib155","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/art.27221","article-title":"Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study","volume":"62","author":"Illei","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib156","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4049\/jimmunol.147.1.117","article-title":"Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis","volume":"147","author":"Linker-Israeli","year":"1991","journal-title":"J\u00a0Immunol"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib157","doi-asserted-by":"crossref","first-page":"625","DOI":"10.7326\/0003-4819-137-7-200210010-00030","article-title":"Infliximab-induced systemic lupus erythematosus","volume":"137","author":"Ali","year":"2002","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.berh.2018.02.001_bib158","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.berh.2018.02.001_bib159","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1191\/0961203302lu236cr","article-title":"Drug-induced lupus following treatment with infliximab in rheumatoid arthritis","volume":"11","author":"Favalli","year":"2002","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib160","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"52","key":"10.1016\/j.berh.2018.02.001_bib161","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001107","article-title":"Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis","volume":"2","author":"Hueber","year":"2010","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib162","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nbt0611-467","article-title":"Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis","volume":"29","author":"Garber","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"7","key":"10.1016\/j.berh.2018.02.001_bib163","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","article-title":"Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550)","volume":"186","author":"Ghoreschi","year":"2011","journal-title":"J\u00a0Immunol"},{"issue":"14","key":"10.1016\/j.berh.2018.02.001_bib164","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1000500","article-title":"An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis","volume":"363","author":"Weinblatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.berh.2018.02.001_bib165","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/exd.13253","article-title":"JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus","volume":"26","author":"Klaeschen","year":"2017","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.berh.2018.02.001_bib166","article-title":"Pharmacokinetics, pharmacodynamics and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","author":"Kim","year":"2017","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.berh.2018.02.001_bib167","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1312625","article-title":"Activated STING in a vascular and pulmonary syndrome","volume":"371","author":"Liu","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2018.02.001_bib168","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.intimp.2017.11.015","article-title":"Propofol attenuates myocardial ischemia reperfusion injury partly through inhibition of resident cardiac mast cell activation","volume":"54","author":"Yu","year":"2017","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.berh.2018.02.001_bib169","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000200","article-title":"Predictors of incident proteinuria among patients with SLE","volume":"4","author":"Duarte-Garcia","year":"2017","journal-title":"Lupus Sci Med"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib170","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.clim.2010.03.008","article-title":"Effect of combining ACE inhibitor and statin in lupus-prone mice","volume":"136","author":"Shimazu","year":"2010","journal-title":"Clin Immunol"},{"issue":"2","key":"10.1016\/j.berh.2018.02.001_bib171","doi-asserted-by":"crossref","first-page":"689","DOI":"10.3892\/etm.2015.2510","article-title":"Early-stage lupus nephritis treated with N-acetylcysteine: a report of two cases","volume":"10","author":"Li","year":"2015","journal-title":"Exp Ther Med"},{"issue":"5","key":"10.1016\/j.berh.2018.02.001_bib172","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s11306-015-0772-0","article-title":"Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin","volume":"11","author":"Perl","year":"2015","journal-title":"Metabolomics"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300032?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694218300032?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:17:53Z","timestamp":1761499073000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694218300032"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":172,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S1521694218300032"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2018.02.001","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Juvenile-onset systemic lupus erythematosus (jSLE) \u2013 Pathophysiological concepts and treatment options","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2018.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}